Letter to the editor: For the core set of the bile lipidome and meta‐proteome signature, repeatability is the key
Shi‐Tao Jiang, Lei Zhang, Yi‐Yao Xu, Xin Lu – 27 April 2022
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato – 27 April 2022 – The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) ha
Reply
Nupur Sharma, Manisha Yadav, Gaurav Tripathi, Babu Mathew, Vasundhra Bindal, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras – 27 April 2022
Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit – 27 April 2022
Letter to the editor: Hepatitis B virus genotype: A significant risk factor in determining which patients with chronic hepatitis B virus infection should undergo surveillance for hepatocellular carcinoma: The hepatitis B Alaska study
Aashish Kumar, Deepak Rajani, Satesh Kumar – 27 April 2022
NAFLD‐related hepatocellular carcinoma: The growing challenge
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison – 27 April 2022 – Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially. Genetic predisposition and clinical risk factors for NAFLD‐related HCC have been identified. Cirrhosis is a well‐known and major risk factor for NAFLD‐related HCC.
Serum Mac‐2 binding protein level predicts the development of liver‐related events and colorectal cancer in patients with NAFLD
Yoshihiro Kamada, Takashi Nakahara, Kensuke Munekage, Hideki Fujii, Yoshiyuki Sawai, Yoshinori Doi, Masafumi Ono, Hideyuki Hyogo, Yoshio Sumida, Koichi Morishita, Tatsuya Asuka, Tsunenori Ouchida, Yasuharu Imai, Eiji Miyoshi, Japan Study Group of NAFLD – 26 April 2022 – We previously demonstrated that Mac‐2 binding protein (M2BP) is a useful biomarker for nonalcoholic fatty liver disease (NAFLD), particularly NAFLD fibrosis prediction. In the present study, we investigated the prognostic value of M2BP in patients with NAFLD.
Palliative Care and Symptom-Based Management in Decompensated Cirrhosis
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
CAQ Corner: Cardiovascular and pulmonary evaluation of liver transplantation candidates: What you need to know for the board exam
Manhal Izzy, Hilary M. DuBrock – 25 April 2022
Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community‐based cohort
Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 25 April 2022